Your cart is currently empty!
Description
Pomalidomide is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013, by the US Food and Drug Administration as a treatment for relapsed and refractory multiple myeloma.
Share This
No more offers for this product!
General Inquiries
There are no inquiries yet.
There are no reviews yet.